

# What to Start: Regimens Recommended for Initial Therapy of Antiretroviral-Naive Children

Updated: Apr.11, 2022

Reviewed: Apr.11, 2022

Panel's Recommendations
<ul style="list-style-type: none"><li>• The selection of an initial antiretroviral (ARV) regimen should be individualized based on several factors, including the characteristics of the proposed regimen, the patient's characteristics, drug efficacy, potential adverse effects, patient and family preferences, and the results of viral resistance testing (<b>AIII</b>).</li><li>• For treatment-naive children, the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) recommends initiating antiretroviral therapy with three drugs: a dual-nucleoside/nucleotide reverse transcriptase inhibitor backbone plus an integrase strand transfer inhibitor, a non-nucleoside reverse transcriptase inhibitor, or a boosted protease inhibitor (<b>AI*</b>).</li><li>• Table 7 below provides a list of Panel-recommended ARV regimens that are designated as <i>Preferred</i> or <i>Alternative</i>; recommendations vary by a patient's age, weight, and sexual maturity rating.</li></ul>
<p><b>Rating of Recommendations:</b> A = Strong; B = Moderate; C = Optional</p> <p><b>Rating of Evidence:</b> I = One or more randomized trials in children<sup>†</sup> with clinical outcomes and/or validated endpoints; I* = One or more randomized trials in adults with clinical outcomes and/or validated laboratory endpoints with accompanying data in children<sup>†</sup> from one or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; II = One or more well-designed, nonrandomized trials or observational cohort studies in children<sup>†</sup> with long-term outcomes; II* = One or more well-designed, nonrandomized trials or observational studies in adults with long-term clinical outcomes with accompanying data in children<sup>†</sup> from one or more similar nonrandomized trials or cohort studies with clinical outcome data; III = Expert opinion</p> <p><sup>†</sup> Studies that include children or children/adolescents, but not studies limited to post-pubertal adolescents</p>

## Criteria Used for Recommendations

In general, the recommendations of the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) are based on reviews of pediatric and adult clinical trial data published in peer-reviewed journals, data prepared by manufacturers for U.S. Food and Drug Administration (FDA) review, and data presented in abstract format at major scientific meetings. Few randomized, Phase 3 clinical trials of antiretroviral therapy (ART) in pediatric patients have directly compared different treatment regimens. Most pediatric drug data come from Phase 1/2 safety and pharmacokinetic (PK) trials and nonrandomized, open-label studies. In general, even in studies of adults, assessment of drug efficacy and potency is primarily based on surrogate marker endpoints, such as CD4 T lymphocyte (CD4) cell count and viral load. The Panel continually modifies recommendations on optimal initial therapy for children as new data become available, as new therapies or drug formulations are developed, and as additional toxicities are recognized.

When developing recommendations for specific drugs or regimens, the Panel considers the following information:

- Data demonstrating durable viral suppression, immunologic improvement, and clinical improvement (when available) with the drug or regimen, preferably in children, as well as adults;
- The extent of pediatric experience with a specific drug or regimen;

- The incidence and types of short-term and long-term drug toxicity in people who are taking the drug or regimen, focusing on toxicities that are reported in children;
- The availability and acceptability of formulations that are appropriate for pediatric use, including palatability, ease of preparation (e.g., syrups vs. powders), pill size, and the number of pills or volume of oral solution needed for an appropriate dose;
- Dosing frequency, and food and fluid requirements; *and*
- The potential for drug interactions with other medications.

The Panel classifies recommended drugs or drug combinations into one of two categories:

- *Preferred*: Drugs or drug combinations are designated as *Preferred* for use in treatment-naïve children when clinical trial data in children or, more often, in adults have demonstrated optimal and durable efficacy with acceptable toxicity and ease of use, and when pediatric studies using surrogate markers have demonstrated safety and appropriate drug exposure. Additional considerations are listed above.
- *Alternative*: Drugs or drug combinations are designated as *Alternative* for initial therapy when clinical trial data in children or adults show efficacy, but the drugs or drug combinations have disadvantages when compared with *Preferred* regimens. Drugs or drug combinations may be classified as *Alternative* for use in treatment-naïve children if they are less effective or durable than a *Preferred* regimen in adults or children; if specific concerns exist about toxicity, dosing, formulation, administration, or interaction; or if experience with the use of these drugs or drug combinations in children is limited.

## Factors to Consider When Selecting an Initial Regimen

An antiretroviral (ARV) regimen for children should generally consist of two nucleoside reverse transcriptase inhibitors (NRTIs) plus an active drug from one of the following classes: an integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a boosted protease inhibitor (PI). Choice of a regimen should be individualized based on several factors, including the characteristics of the proposed regimen; the patient's age, weight, sexual maturity rating (SMR), and other characteristics; and the results of drug-resistance testing.

Drug recommendations often include both age and weight limitations. Although age can be used as a rough guide, body weight (when available) is the preferred determinant for selecting a specific drug. An exception to this is infants aged <14 days. Many drugs that are recommended for use in very young infants do not have dosing recommendations for premature infants. Additional information regarding dosing recommendations in this population can be found in [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#).

The advantages and disadvantages of each regimen are described in detail in the sections that follow and in Table 8 below. Additional information regarding the advantages and disadvantages of specific drug combinations can be found in the [What to Start](#) section of the [Adult and Adolescent Antiretroviral Guidelines](#). Specific information about the clinical efficacy, adverse events (AEs), and dosing recommendations for each drug can be found in [Appendix A: Pediatric Antiretroviral Drug Information](#). In addition, clinicians should consider potential barriers to adherence. These barriers may include complex dosing schedules, food requirements, palatability problems, and the need to use multiple formulations to achieve an appropriate dose. Counseling patients and caregivers about adherence to therapy is essential for successful ART. The Panel recommends rapid initiation of ART (defined as initiating ART immediately or within days of diagnosis).

Emtricitabine (FTC), lamivudine (3TC), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) have antiviral activity and efficacy against hepatitis B virus (HBV) and should be considered for use in children with HBV/HIV coinfection. For a comprehensive review, see the [Hepatitis B Virus](#), [Hepatitis C Virus](#), and [Mycobacterium tuberculosis \(TB\)](#) sections of the [Pediatric Opportunistic Infection Guidelines](#).

## Choosing an Initial Antiretroviral Regimen for Children with HIV

Preferred regimens for initial ARV therapy include INSTI-based, NNRTI-based, or boosted PI-based regimens. A regimen should be chosen after considering the patient's individual characteristics (especially age), the results of drug-resistance testing, potential AEs, pill size, and dosing frequency. Adherence to a prescribed regimen is necessary; therefore, the preferences of the patient and caregivers also should be considered when choosing a regimen.

Clinical trial data in children provide some guidance for choosing between an NNRTI-based regimen and a PI-based regimen for initial therapy. Three pediatric studies have compared an NNRTI-based regimen to a PI-based regimen, and results varied based on the age of the population studied and the specific drug used within the class.

- The IMPACT ([International Maternal Pediatric adolescent AIDS Clinical Trials](#)) P1060 study demonstrated the superiority of a lopinavir/ritonavir (LPV/r)-based regimen over a nevirapine (NVP)-based regimen in infants and children aged 2 months to 35 months, regardless of maternal or infant exposure to peripartum, single-dose NVP prophylaxis. In children with prior NVP exposure, 21.7% of children receiving the LPV/r-based regimen experienced death, virologic failure, or toxicity by Week 24 compared with 39.6% of children receiving the NVP-based regimen. For children with no prior NVP exposure, death, virologic failure, and toxicity occurred in 18.4% of children receiving the LPV/r-based regimen and in 40.1% of children receiving the NVP-based regimen.<sup>1</sup>
- Those in the NVP group demonstrated greater, but not statistically significant, improvements in CD4 counts and growth parameters. However, improvements in CD4 counts were maintained only up to 1 year after initiation of ART.<sup>2</sup> Similar improved immune and growth parameters were reported in the Nevirapine Resistance ([NEVEREST](#)) study, where these parameters were compared in children who were switched to an NVP-containing regimen and those who were continued on an LPV/r-containing regimen after achieving virologic suppression.<sup>3</sup> Improvements in metabolic parameters also have been seen in children who were switched from LPV/r to efavirenz (EFV) at or after 3 years of age.<sup>4</sup>
- [PENPACT-1 \(PENTA 9/PACTG 390\)](#) compared a PI-based regimen and an NNRTI-based regimen in treatment-naïve children aged 30 days to <18 years (the study did not dictate the use of specific NNRTIs or PIs). In the PI-based regimen group, 49% of children received LPV/r and 48% received nelfinavir; in the NNRTI-based regimen group, 61% of children received EFV and 38% received NVP. After 4 years of follow-up, 73% of children who were randomized to receive PI-based therapy and 70% who were randomized to receive NNRTI-based therapy remained on their initial ARV regimen. In both groups,<sup>5</sup> 82% of children had viral loads <400 copies/mL.
- The [PROMOTE pediatrics trial](#) demonstrated comparable virologic efficacy among children who were randomized to receive either an NNRTI-based or an LPV/r-based ARV regimen.<sup>6</sup> Children were aged 2 months to <6 years and had no perinatal exposure to NVP. Selection of the NNRTI was based on age (children aged <3 years received NVP, and those aged >3 years primarily received EFV). The proportion of children with viral loads <400 copies/mL at 48 weeks was 80%

in the LPV/r arm versus 76% in the NNRTI arm, a difference of 4% that was not statistically significant (95% confidence interval [CI], -9% to +17%).

Clinical investigation of INSTI-based regimens in children has been limited to noncomparative studies that have evaluated the safety, tolerability, and PKs of these drugs. The recommendation for using an INSTI as part of an initial regimen is based largely on extrapolation from adult comparative trials—which showed that INSTI-containing regimens have superior efficacy when compared to PI-containing and NNRTI-containing regimens<sup>7,8</sup>—and small studies in ART-naïve adolescents.<sup>9</sup>

When combined with two NRTIs, the following drugs and drug combinations are considered *Preferred initial* regimens for children:

- Newborns aged <14 days: NVP
- Newborns aged <4 weeks and weighing  $\geq 2$  kg: Raltegravir (RAL)
- Newborns aged  $\geq 14$  days to <4 weeks: LPV/r
- Infants and children aged  $\geq 4$  weeks and weighing  $\geq 3$  kg: Dolutegravir (DTG)
- Children aged  $\geq 2$  years and weighing  $\geq 14$  kg: DTG or Bictegravir (BIC). BIC is available only as a component of the fixed-dose combination (FDC) tablet BIC/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).

*Preferred initial regimens* by age, weight, and drug class are shown in Figure 1 below. *Additional information about Preferred initial regimens, Preferred NRTI backbones, Alternative initial regimens, and Alternative NRTI backbones* are shown in detail in Table 7 below.

## Integrase Strand Transfer Inhibitor-Based Regimens

Four INSTIs—BIC, DTG, elvitegravir (EVG), and RAL—are approved by the FDA for treating ARV-naïve adults and children with HIV. INSTI-based regimens have quickly become the recommended regimens in adults due to their virologic efficacy, lack of drug interactions, and favorable toxicity profile. RAL is approved for the treatment of infants and children from birth onward with a weight of  $\geq 2$  kg. DTG is approved by the FDA for use in infants and children aged  $\geq 4$  weeks and weighing  $\geq 3$  kg. The FDC tablet BIC/FTC/TAF (Biktarvy) is approved by the FDA for use in children weighing  $\geq 14$  kg. EVG has been studied in adolescents in two FDC regimens and in combination with two NRTIs and ritonavir (RTV, r) boosting. BIC and DTG, the second-generation INSTIs, have higher barriers to resistance than the first-generation INSTIs RAL and EVG<sup>10,11</sup> and may have more activity against non-B subtypes of HIV.<sup>12,13</sup>

Table 8 below lists the advantages and disadvantages of using INSTIs. See [Appendix A: Pediatric Antiretroviral Drug Information](#) for detailed pediatric information on each drug.

*Preferred* and *Alternative* INSTIs are presented in **alphabetical** order below.

### *Bictegravir*

BIC/FTC/TAF was approved by the FDA in 2018 for use in adults and in 2019 for use in children or adolescents weighing  $\geq 25$  kg. In October 2021, a lower strength formulation of BIC/FTC/TAF received FDA approval for use in children weighing  $\geq 14$  kg to <25 kg. BIC/FTC/TAF is approved for use in patients who are ART naïve, and it also can be used to replace the current ARV regimen in patients who have been virologically suppressed (viral load <50 copies/mL) on a stable ARV

regimen, with no history of treatment failure, and no known substitutions associated with resistance to the individual components of the FDC tablet.

BIC/FTC/TAF has been studied in adolescents (Cohort 1) aged 12 years to <18 years and weighing  $\geq 35$  kg and in two younger cohorts of children: Cohort 2, aged 6 years to <12 years who weighed  $\geq 25$  kg, and Cohort 3, aged  $\geq 2$  years and who weighed  $\geq 14$  kg to <25 kg. All participants had maintained viral loads <50 copies/mL for  $\geq 6$  months. Cohorts 1 and 2 received the adult formulation of BIC/FTC/TAF. Children in Cohort 3 received BIC 30 mg/FTC 120 mg/TAF 15 mg. Overall, the drug was well tolerated in all participants in all cohorts. Drug exposure in all cohorts was similar to the exposure observed in adults. At 24 weeks, all 50 adolescents and 50 children in Cohorts 1 and 2 maintained viral suppression and at Week 48, 49 of 50 participants in each cohort maintained suppression.<sup>14-18</sup> Among children in Cohort 3, after 24 weeks, all 12 participants maintained viral suppression.<sup>17,18</sup>

### Recommendation

- BIC/FTC/TAF is recommended as a *Preferred* INSTI-based regimen for children aged  $\geq 2$  years and weighing  $\geq 14$  kg (AI\*). The Panel bases this recommendation on the virologic potency and safety profile observed for this combination in adult and pediatric studies.

### *Dolutegravir*

DTG is approved by the FDA for use in infants and children  $\geq 4$  weeks and weighing  $\geq 3$  kg. This recommendation is based on PK and safety data from two ongoing clinical trials ([IMPAACT P1093](#) and [ODYSSEY](#)), as well as a study of treatment-experienced (but INSTI-naive) older children.<sup>9,19-21</sup>

Early data from Botswana about the use of DTG around the time of conception showed a small significant increase in the prevalence of neural tube defects (NTDs) that has decreased over time.<sup>17,22,23,24</sup> In the most recent analysis of data from this study, the prevalence of NTDs did not differ significantly between women receiving DTG and non-DTG regimens.<sup>24</sup> For additional information, refer to [Teratogenicity, Recommendations for Use of Antiretroviral Drugs During Pregnancy](#), and [Appendix C: Antiretroviral Counseling Guide for Health Care Providers](#) in the [Perinatal Guidelines](#).

### Recommendation

- DTG plus a two-NRTI backbone is recommended as a *Preferred* INSTI-based regimen for infants, children, and adolescents aged  $\geq 4$  weeks and weighing  $\geq 3$  kg (AI\*). The Panel bases this recommendation on the virologic potency and safety profile observed for this combination in adult and pediatric studies.<sup>7,9,21,25,26</sup>
- Early concerns about the potential increased risk of NTDs with the use of DTG in women who were receiving DTG at the time of conception have decreased substantially. The Panel for [Antiretroviral Guidelines for Adults and Adolescents](#) and the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission include DTG among the preferred ARV agents for use in people of childbearing potential and for use by people who are pregnant or are trying to conceive. Pediatric and adolescent care providers should discuss risks and benefits with patients (and their caregivers) who are receiving or initiating DTG so that they can make informed decisions about the use of DTG (see [Appendix C: Antiretroviral Counseling Guide for Health Care Providers](#) in the [Perinatal Guidelines](#)).

## *Elvitegravir*

EVG is an INSTI that is available as a single-drug tablet, an FDC tablet that contains EVG/cobicistat (COBI, c)/FTC/TDF, and an FDC tablet that contains EVG/c/FTC/TAF. Both FDC tablets are approved by the FDA for use in ART-naïve adults with HIV. EVG/c/FTC/TAF is approved for use in ART-naïve children and adolescents weighing  $\geq 25$  kg. COBI, c is a specific, potent cytochrome P450 (CYP) 3A inhibitor that has no activity against HIV. It is used as a PK enhancer, which allows once-daily dosing of EVG.

### **Recommendation**

- EVG/c/FTC/TAF is recommended as an *Alternative* INSTI-based regimen for children and adolescents weighing  $\geq 25$  kg who have creatinine clearance (CrCl)  $\geq 30$  mL/min (**AI\***). The Panel bases this recommendation on the virologic potency and safety profile observed for this combination in adult and adolescent studies. The Panel does not recommend EVG/c/FTC/TAF as a *Preferred* INSTI-based regimen because EVG has a lower barrier to resistance compared with BIC or DTG and the potential for multiple drug–drug interactions from COBI.<sup>27-31</sup>

## *Raltegravir*

RAL is approved by the FDA for treatment of infants and children weighing  $\geq 2$  kg, and it can be used starting at birth. It is available in film-coated tablets, chewable tablets, and single-use packets of granules for oral suspension. Clinicians should consult with an expert in pediatric HIV infection when initiating RAL-based treatment regimens in neonates, infants, and very young children.

Additional information can be found in [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#).

### **Recommendation**

- RAL plus a two-NRTI backbone is recommended as a *Preferred* INSTI-based regimen for infants and children from birth to age 4 weeks who weigh  $\geq 2$  kg (**AI\***). It is an *Alternative* INSTI-based regimen for children aged  $\geq 4$  weeks due to its twice-daily dosing requirement and lower barrier to resistance compared with other INSTIs (**AI\***). The Panel bases this recommendation on data from randomized clinical trials in adults and pediatric studies that were performed largely in ARV-experienced children and adolescents.<sup>7,32-40</sup>
- Currently, the Panel **does not recommend** once-daily dosing of RAL for initial therapy in children and infants.

## **Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens**

Doravirine (DOR; for children weighing  $\geq 35$  kg), EFV (for children aged  $\geq 3$  months), etravirine (ETR; for children aged  $\geq 6$  years), NVP (for children aged  $\geq 15$  days), and rilpivirine (RPV; for children aged  $\geq 12$  years) have been approved by the FDA for treatment of HIV infection in pediatric patients. NNRTIs have a long half-life that allows less frequent drug administration; a lower risk of dyslipidemia and fat maldistribution than some agents in the PI class; and, generally, a lower pill burden than PIs. However, a single viral mutation can confer high-level drug resistance to all NNRTIs except ETR, and cross-resistance to other NNRTIs is common. Rare, but serious and potentially life-threatening, skin and hepatic toxicity can occur with the use of all NNRTI drugs, but these AEs are most frequently observed in patients taking NVP, at least among adults with HIV. NNRTIs have the potential to interact with other drugs that are also metabolized via hepatic

enzymes; however, these drug interactions are less frequent with NNRTIs than with boosted-PI regimens. Table 8 below lists the advantages and disadvantages of using NNRTIs. See [Appendix A: Pediatric Antiretroviral Drug Information](#) for detailed pediatric information for each drug.

*Preferred* and *Alternative* NNRTIs are presented in **alphabetical** order below.

### ***Doravirine***

DOR is available both as a single-drug tablet and an FDC tablet that contains DOR 100 mg/3TC 300 mg/TDF 300 mg, marketed as Delstrigo. Efficacy studies in adults have demonstrated that DOR/3TC/TDF is noninferior to EFV-based regimens and darunavir (DRV)-based regimens. Virologic efficacy of DOR was similar in patients with higher viral loads >100,000 copies/mL as to those with viral loads ≤100,000 copies/mL. DOR, more so than EFV, compared favorably to the other drugs in these trials in terms of AEs (including better central nervous system tolerability) and is recommended as initial ART in adults with certain clinical situations. The FDC tablet has been studied in 45 adolescents aged 12 years to 17 years and weighing ≥45 kg. Of these adolescents, 43 were virologically suppressed and 2 were ART-naive. After 24 weeks of treatment, the regimen was well tolerated, with a low incidence of drug-related AEs (2.2%; 95% CI, 0.1–11.8). None of the AEs were serious or led to regimen discontinuation. HIV-1 RNA <50 copies/mL was demonstrated in all participants except for one ART-naive participant who met the criteria for virologic failure based on poor adherence to the study regimen.<sup>44</sup>

### **Recommendation**

- DOR plus a two-NRTI backbone is recommended as an *Alternative* NNRTI-based regimen for initial treatment of HIV in children and adolescents weighing ≥35 kg (**BI\***). The Panel bases this recommendation on data from studies that evaluated the efficacy and tolerability of this drug in adults,<sup>41-43</sup> as well as early findings from pediatric PK studies.<sup>44</sup>

### ***Efavirenz***

Although EFV dosing recommendations are available for patients aged ≥3 months and weighing ≥3.5 kg, the Panel does not endorse the use of this drug in infants and children aged 3 months to 3 years because the PKs of EFV in very young patients can be highly variable. There may be a role for use of EFV in children aged <3 years who have HIV and TB coinfection, because EFV is one of the few ARVs with minimal drug–drug interaction.<sup>45</sup>

### **Recommendation**

- EFV plus a two-NRTI backbone is recommended as an *Alternative* NNRTI-based regimen for initial treatment of HIV in children aged ≥3 years (**AI\***). The Panel bases this recommendation on data from studies that evaluated the efficacy and tolerability of this drug in adults and children.<sup>25,32,46-63</sup>

### ***Nevirapine***

Extensive clinical and safety data exist for the use of NVP in children with HIV, and NVP has shown ARV efficacy when used as a component in a variety of combination regimens.<sup>1,5,6,64-68</sup> NVP also has been used extensively as prophylaxis for the prevention of HIV transmission in young infants during the peripartum period and during breastfeeding.<sup>69</sup> The safety and PKs of NVP have been studied at low doses used for prophylaxis. Less information is currently available from studies in very young infants about the safety and PKs of NVP at the higher doses required for treatment.

Early testing of infants allows HIV infection to be confirmed before 14 days of age. The Panel recommends the use of NVP as a *Preferred* NNRTI when a clinician plans to initiate treatment before age 14 days. **Although early treatment initiation may limit the size of the viral reservoir,**<sup>70,71</sup> no clinical trial data currently suggest that initiating treatment within the first 14 days of life improves outcomes compared to starting treatment after age 14 days (see **When to Initiate Therapy in Antiretroviral-Naive Children**). Clinicians should consult an expert in pediatric HIV infection when considering the use of NVP in infants aged <14 days. Additional considerations regarding the use of NVP in infants aged <14 days can be found in [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#).

## Recommendation

- NVP plus a two-NRTI backbone is recommended as a *Preferred* NNRTI-based regimen in infants aged <14 days and as an *Alternative* NNRTI-based regimen for children aged ≥14 days to <3 years (**AI**). Clinicians should consider switching from NVP to LPV/r or RAL in children aged ≥14 days to <4 weeks because these drugs are the *Preferred* ARV agents for this age bracket. LPV/r has better clinical outcomes than NVP in children aged <3 years. The Panel recommends switching from NVP to LPV/r in these patients because NVP is associated with rare occurrences of significant hypersensitivity reactions, including Stevens-Johnson syndrome, and rare (but potentially life-threatening) instances of hepatitis. NVP also has a low barrier to resistance, and conflicting data exist about the virologic efficacy of NVP-based regimens compared to the efficacy of *Preferred* regimens.<sup>1,5,6,66-68,72-79</sup>

## Rilpivirine

RPV is currently available both as a single-drug tablet and a once-daily FDC tablet that contains FTC/RPV/TDF. The single-drug tablet is approved for use in children and adolescents aged ≥12 years.

RPV also is available as an extended-release injectable suspension in a kit that contains an extended-release injectable cabotegravir (CAB) suspension. The two-drug regimen of injectable CAB and RPV is approved for treatment of HIV-1 infection in adults with viral suppression; it is not approved for initial therapy. This regimen is under study in adolescents.

## Recommendation

- RPV plus a two-NRTI backbone is recommended as an *Alternative* NNRTI-based regimen for children and adolescents aged ≥12 years and weighing ≥35 kg who have HIV viral loads ≤100,000 copies/mL (**AI\***). The Panel bases this recommendation on the limited experience with RPV in adolescents and the larger body of evidence in adults.<sup>53,80-83</sup>

## Protease Inhibitor-Based Regimens

Advantages of PI-based regimens include excellent virologic potency and a high barrier to drug resistance (because multiple mutations are required for a patient to develop resistance). However, because PIs are metabolized via hepatic enzymes, these drugs have the potential for multiple drug interactions. They also may be associated with metabolic complications, such as dyslipidemia, fat maldistribution, and insulin resistance. Factors to consider when selecting a PI-based regimen for treatment-naïve children include virologic potency, dosing frequency, pill burden, food or fluid requirements, the availability of palatable pediatric formulations, the drug interaction profile, the toxicity profile (particularly toxicities related to metabolic complications), the age of the child, and



the availability of data regarding the use of the drug in children. Table 8 below lists the advantages and disadvantages of using PIs. See [Appendix A: Pediatric Antiretroviral Drug Information](#) for detailed pediatric information on each drug.

RTV is a potent inhibitor of the CYP3A4 isoenzyme and can be used in low doses as a PK booster when coadministered with some PIs, increasing drug exposure by prolonging the half-life of the boosted PI. Currently, only LPV/r is available as a coformulated product. In addition, the use of RTV boosting increases the risk of hyperlipidemia<sup>84</sup> and drug interactions. COBI is an alternative CYP3A4 inhibitor that also can be used as a booster. It is available in a single-drug tablet and in coformulations with atazanavir (ATV) and with DRV. Currently, the single-drug tablet is approved by the FDA for administration with ATV in children weighing  $\geq 35$  kg and for administration with DRV in children weighing  $\geq 40$  kg.

*Preferred* and *Alternative* PIs are presented in **alphabetical** order below.

### ***Atazanavir Boosted with Ritonavir or Cobicistat***

ATV is a once-daily PI that was approved by the FDA in March 2008 for use in combination with a two-NRTI backbone in children aged  $\geq 6$  years. ATV is most often boosted with RTV. Approval was extended in 2014 for use in infants and children aged  $\geq 3$  months and weighing  $\geq 5$  kg.<sup>85,86</sup> ATV administered in combination with COBI has been approved by the FDA for use in adults (using the single-agent COBI tablet) and in children weighing  $\geq 35$  kg.

#### **Recommendation**

- ATV/r plus a two-NRTI backbone is recommended as an *Alternative* PI-based regimen for children aged  $\geq 3$  months (**AI\***). ATV/c plus a two-NRTI backbone is an *Alternative* PI-based regimen for children weighing  $\geq 35$  kg. These regimens have been shown to be virologically potent in adult and pediatric studies and have been well tolerated in pediatric studies. However, the oral powder formulations of ATV and RTV and the oral solution formulation of RTV can be cumbersome to administer.<sup>35,49,82,84,87-92</sup>
- The Panel **does not recommend** the use of unboosted ATV.

### ***Darunavir Boosted with Ritonavir or Cobicistat***

DRV/r is approved by the FDA for use in ARV-naïve and ARV-experienced children aged  $\geq 3$  years and weighing  $\geq 10$  kg. In addition, once-daily dosing of DRV/r is approved for ARV-naïve children aged  $\geq 3$  years and weighing  $\geq 10$  kg, and for ARV-experienced patients who do not have DRV resistance-associated mutations. Once-daily dosing of DRV/r was investigated during a substudy of a twice-daily dosing trial in children aged 3 years to  $< 12$  years. This PK evaluation lasted only 2 weeks, after which the participants were switched back to the twice-daily regimen.<sup>93</sup> FDA dosing recommendations are based on PK models from this study, but this dose has never undergone trials for clinical efficacy in this age group. A more recent study also suggested that once-daily DRV/r dosing is acceptable for children and adolescents. In this study, the plasma concentration-time curve for DRV/r was substantially lower than the mean value observed in adults; however, trough levels were similar. Due to these findings, and because of the lack of more information about the efficacy of once-daily DRV/r dosing in ARV-naïve and ARV-experienced children aged  $< 12$  years, the Panel recommends a twice-daily dose of DRV/r in children aged  $> 3$  years to  $< 12$  years.<sup>94</sup> DRV administered in combination with COBI has been approved by the FDA for use in adults (using the single-agent COBI tablet) and in children weighing  $\geq 40$  kg.<sup>95</sup>

## Recommendation

- DRV/r plus a two-NRTI backbone is recommended as an *Alternative* PI-based regimen for children aged  $\geq 3$  years and weighing  $\geq 10$  kg (**AI\***). The Panel bases these recommendations on the virologic potency shown by DRV/r in adult and pediatric studies, and this combination's high barrier to the development of drug resistance and excellent toxicity profile in adults and children.<sup>35,96-103</sup>
- Based on findings from the DIONE study, once-daily dosing of DRV/r is part of an *Alternative* PI-based regimen in ARV-naive children and adolescents weighing  $\geq 40$  kg (**AI\***).
- Twice-daily dosing of DRV/r should be used for children aged  $\geq 3$  years to  $< 12$  years.
- Twice-daily dosing of DRV/r should be used when the following DRV resistance-associated substitutions are present in the HIV protease: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V.
- DRV/c plus a two-NRTI backbone is recommended as an *Alternative* PI-based regimen for adolescents aged  $\geq 12$  years and weighing  $\geq 40$  kg who are not sexually mature.

## Lopinavir/Ritonavir

LPV/r is approved to treat HIV infection in infants and children with a postmenstrual age  $\geq 42$  weeks and postnatal age  $\geq 14$  days. Once-daily LPV/r dosing is approved by the FDA for initial therapy in adults,<sup>104</sup> but PK data in children do not support a recommendation for once-daily dosing.<sup>105,106</sup>

## Recommendation

LPV/r plus a two-NRTI backbone is recommended as a *Preferred* PI-based regimen for infants with a postmenstrual age  $\geq 42$  weeks and postnatal age  $\geq 14$  days to  $< 4$  weeks (**AI**) and as an *Alternative* PI-based regimen in children aged  $\geq 4$  weeks (**AI\***). This regimen has been shown to be virologically potent in adult and pediatric studies and has been well tolerated in pediatric studies. Although it is recommended only as a *Preferred* PI-based regimen for a narrow age range, use of LPV/r is supported by many Panel members as a *Preferred* PI-based regimen in children up to 3 years of age due to extensive experience with this drug and ease of administering a liquid formulation in infants and very young children.<sup>25,51,87,88,96,104-111</sup>

## Selection of Dual-Nucleoside Reverse Transcriptase Inhibitor Backbone as Part of Initial Combination Therapy

Dual-NRTI combinations form the backbone of combination regimens for both adults and children. The advantages and disadvantages of the different dual-NRTI backbone options that are recommended for initial therapy in children are listed in Table 8 below.<sup>14,31,59,89,112-116</sup>

See [What Not to Start](#) for more information. Also, see [Appendix A: Pediatric Antiretroviral Drug Information](#) for detailed pediatric information on each drug.

In the dual-NRTI backbones listed below, 3TC and FTC are interchangeable. Both 3TC and FTC are well tolerated and have few AEs. FTC is similar to 3TC and can be substituted for 3TC as one component of a *Preferred* dual-NRTI backbone (i.e., FTC used in combination with ABC, TDF, or zidovudine [ZDV]). The main advantage of FTC over 3TC is that it can be administered once daily as part of an initial regimen. Both 3TC and FTC select for the M184V resistance mutation, which is

associated with high-level resistance to both drugs, a modest decrease in susceptibility to ABC, and improved susceptibility to ZDV and TDF as a result of decreased viral fitness.<sup>117,118</sup>

The Panel no longer recommends using didanosine or stavudine as part of ARV regimens for children due to the significant toxicities observed when using these drugs and the availability of safer agents. These drugs are no longer commercially available for use in general.

Dual-NRTI combinations are presented in **alphabetical** order below.

### ***Abacavir in Combination with Lamivudine or Emtricitabine***

ABC is approved by the FDA for use in children aged  $\geq 3$  months when administered as part of an ARV regimen. ABC also has been reported to be safe in infants and children aged  $\geq 1$  month. More recently, an ABC dosing recommendation using PK simulation models has been endorsed by the World Health Organization using weight-band dosing for full-term infants from birth to 1 month of age. Based on this endorsement, the Panel recommends ABC from birth in full-term infants testing negative for the HLA-B5701 allele.<sup>119,120</sup>

#### **Recommendation**

- ABC plus 3TC or FTC is recommended as the *Preferred* dual-NRTI combination for children aged  $\geq 3$  months (**AI**) and for full-term infants from birth (**BIII**). A negative test for the HLA-B5701 allele should be obtained prior to starting ABC regardless of age.
- Studies of adults and children have reported virologic efficacy and favorable toxicity profiles for these combinations.<sup>33,121-128</sup> Recent data from the [IMPAACT P1106](#) trial and two observational cohorts provide reassuring data on the safety of ABC in infants when initiated at age  $< 3$  months.<sup>129-131</sup> Additional information about the use of ABC between birth and 1 month of age can be found in the [Appendix A: Pediatric Antiretroviral Drug Information](#). Due to ABC-associated hypersensitivity, negative testing for HLA-B5701 allele should be confirmed before administration of ABC.
- Once-daily dosing is recommended when using the pill formulation of ABC. Twice-daily dosing of liquid ABC is recommended for initial therapy; a change to once-daily dosing can be considered for clinically stable patients with undetectable viral loads and stable CD4 counts.<sup>132-135</sup>

### ***Tenofovir Alafenamide in Combination with Emtricitabine***

TAF is an oral prodrug of tenofovir. It is approved by the FDA as a component of an FDC tablet that also contains EVG, COBI, and FTC for the treatment of HIV in ARV-naïve individuals weighing  $\geq 25$  kg who have an estimated CrCl  $\geq 30$  mL/min. Additional safety and PK data are available for children aged 6 years to  $< 12$  years who are receiving this FDC tablet.<sup>30</sup> TAF formulated as an FDC tablet with FTC and BIC is FDA approved for use in children weighing  $\geq 14$  kg (see [Bictegravir](#)).<sup>14,136</sup> An FDC tablet that contains FTC/TAF (Descovy) is available for use in children weighing  $\geq 14$  kg, with dosage determined by a child's weight. In January 2022, the FDA approved a lower strength formulation of the FTC/TAF FDC tablet for use in children weighing  $\geq 14$  kg to  $< 25$  kg.<sup>137</sup>

Coadministration of TAF with boosted ATV, DRV, or LPV increases TAF exposure to concentrations that are higher than those seen with use of EVG/c/FTC/TAF. Because no data exist on the use of this combination in children weighing  $< 35$  kg, the safety of FTC/TAF combined with

COBI-boosted or RTV-boosted PIs in children weighing <35 kg cannot be assured and is not recommended.

### Recommendation

- FTC/TAF is recommended as a *Preferred* dual-NRTI combination in children and adolescents weighing  $\geq 14$  kg with estimated CrCl  $\geq 30$  mL/min when used with an INSTI or NNRTI. **FTC/TAF** is a *Preferred* dual-NRTI combination when used with a PI in children and adolescents weighing  $\geq 35$  kg who have estimated CrCl  $\geq 30$  mL/min (**AI\***). **FTC/TAF** also is recommended as a *Preferred* drug combination when used in the regimen **BIC/FTC/TAF** for children and adolescents weighing  $\geq 14$  kg (**AI\***). EVG/c/FTC/TAF is recommended as an *Alternative* drug regimen for children and adolescents weighing  $\geq 25$  kg (**AI\***). The Panel makes these recommendations because TAF has a lower risk of renal and bone AEs than TDF.
- FTC/TAF is neither approved by the FDA nor recommended for use in combination with a boosted PI in children weighing <35 kg, because this combination has not been adequately studied in this age and weight group.

### *Tenofovir Disoproxil Fumarate in Combination with Lamivudine or Emtricitabine*

TDF is approved by the FDA for use in children and adolescents aged  $\geq 2$  years when administered as part of an ARV regimen. Decreases in bone mineral density (BMD) have been observed in adults and children receiving TDF, but the clinical significance of these decreases is unknown.<sup>113-116,140,141</sup> Before starting treatment, clinicians should consider whether the benefits of using TDF outweigh the potential risk of decreased BMD.<sup>142</sup>

### Recommendation

- TDF plus 3TC or FTC is recommended as an *Alternative* dual-NRTI combination for children aged  $\geq 2$  years to 12 years (**AI\***). The Panel bases this recommendation on the virologic efficacy and ease of dosing of these combinations.<sup>113-116,122-125,143-148</sup>

### *Zidovudine in Combination with Abacavir*

In a European pediatric study, patients who received ZDV plus ABC had lower rates of viral suppression and a greater number of toxicities that led to regimen modification than in patients who received ABC plus 3TC.<sup>112,121</sup> Recent data from the IMPAACT P1106 trial and two observational cohorts provide reassuring data on the safety of ABC in infants when initiated at age <3 months.<sup>129-131</sup>

### Recommendation

- ZDV plus ABC is recommended as an *Alternative* dual-NRTI combination for children aged  $\geq 1$  month (**BII**).

### *Zidovudine in Combination with Lamivudine or Emtricitabine*

ZDV is available as a syrup, a capsule, and a tablet, and it is also available in injectable/intravenous preparations. It is approved by the FDA for treatment of HIV in infants aged  $\geq 4$  weeks and for prophylaxis in newborns.

## Recommendation

- ZDV plus 3TC or FTC is recommended as a *Preferred* dual-NRTI combination for infants and children from birth to age  $\leq 1$  month, and as an *Alternative* combination in children aged  $\geq 1$  month and adolescents (**AI\***). Twice-daily dosing is required for all ages with ZDV. Other NRTIs that require only once-daily dosing in children aged  $\geq 6$  years are available.<sup>126,149-151</sup>
- In children aged  $\geq 6$  years and adolescents who are not sexually mature (i.e., those with SMRs of 1–3), the Panel recommends ZDV plus 3TC or FTC as an *Alternative* dual-NRTI combination (**BII**).

**Figure 1. Preferred Regimen by Age, Weight, and Drug Class**

	Patient Age and Weight Class				
	Birth to <14 Days of Age <sup>a,b,c</sup>	Aged $\geq 14$ Days and $\geq 2$ kg to < 4 Weeks	Aged $\geq 4$ Weeks and $\geq 3$ kg to < 2 Years	Aged $\geq 2$ Years and $\geq 14$ kg	Aged $\geq 6$ Years and $\geq 25$ kg
INSTI-Based Regimens	Two NRTIs plus RAL <sup>c</sup>				
				Two NRTIs plus BIC <sup>d</sup>	
	Two NRTIs plus DTG <sup>c</sup>				
NNRTI-Based Regimens	Two NRTIs plus NVP <sup>a,f</sup>				
PI-Based Regimens	Two NRTIs plus LPV/r <sup>b</sup>				

<sup>a</sup> Preferred NRTIs are listed in Table 7 below.

If treatment is scheduled to begin before a patient is aged 14 days, NVP or RAL are *Preferred* agents because they are the only options with dosing information available for this age group. Although many pediatric experts favor initiating antiretroviral therapy as soon as possible after birth to limit the establishment of viral reservoirs, available clinical trial data do not suggest that initiating treatment within the first 14 days of life leads to better clinical outcomes than initiating treatment after 14 days of age. Clinicians should consult an expert in pediatric HIV infection before initiating treatment in infants aged <14 days. Additional considerations regarding the use of NVP or RAL in infants aged <14 days can be found in [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#). Switching from NVP to LPV/r should be considered when the infant is aged  $\geq 14$  days with a postmenstrual age of 42 weeks (the span of time between the first day of the mother's last menstrual period and birth, plus the time elapsed after birth); LPV/r has produced better clinical outcomes than NVP in studies of children aged <3 years. Data are limited on the clinical outcomes of using RAL in infants and children aged <2 years.

<sup>b</sup> In general, LPV/r **should not be administered** to neonates before a postmenstrual age of 42 weeks and a postnatal age of  $\geq 14$  days (see the [Lopinavir/Ritonavir](#) section in [Appendix A: Pediatric Antiretroviral Drug Information](#)).

<sup>c</sup> RAL granules can be administered to infants and children weighing  $\geq 2$  kg from birth to age 2 years. Oral RAL granules can be used up to a dose of 100 mg in the 14 kg to  $< 20$  kg weight band. RAL pills or chewable tablets can be used in children aged  $\geq 2$  years. Chewable RAL tablets can be crushed and dispersed in liquid to infants as young as 4 weeks of age who weigh at least 3 kg.

<sup>d</sup> BIC is available only as part of a fixed-dose combination (FDC) tablet that contains BIC/FTC/TAF; this FDC tablet is recommended as a *Preferred* regimen for children aged  $\geq 2$  years and weighing  $\geq 14$  kg. Two strengths of BIC/FTC/TAF are available, with dosing according to a child's weight (see [Bictegravir](#)).

<sup>e</sup> DTG is recommended as a *Preferred* agent for infants, children, and adolescents aged  $\geq 4$  weeks and weighing  $\geq 3$  kg. DTG dispersible tablets can be administered in infants and children aged  $\geq 4$  weeks and weighing  $\geq 3$  kg. DTG film-coated tablets can be used in children weighing  $\geq 14$  kg. An FDC tablet that contains ABC/DTG/3TC (Triumeq) is available for children weighing  $\geq 25$  kg.

<sup>f</sup> NVP should not be used in post-pubertal girls with CD4 T lymphocyte cell counts  $> 250/\text{mm}^3$ , unless the benefit clearly outweighs the risk. NVP is approved by the U.S. Food and Drug Administration for the treatment of infants aged  $\geq 15$  days.

**Key:** BIC = bictegravir; DTG = dolutegravir; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; TAF = tenofovir alafenamide

**Table 7. Antiretroviral Regimens Recommended for *Initial* Therapy for HIV Infection in Children**

An antiretroviral (ARV) regimen for treatment-naïve children is generally made up of a two–nucleoside reverse transcriptase inhibitor (NRTI) backbone and either one non-nucleoside reverse transcriptase inhibitor (NNRTI) **or** one integrase strand transfer inhibitor (INSTI) **or** one protease inhibitor (PI) boosted with ritonavir or cobicistat (COBI). Regimens are designated *Preferred* based on efficacy, ease of administration, and acceptable toxicity. *Alternative* regimens also have demonstrated efficacy, but clinical experience with these regimens is limited, or these regimens are more difficult to administer than *Preferred* regimens. Regimens should be tailored to the individual patient by weighing the advantages and disadvantages of each combination. Many agents have multiple formulations and age and weight recommendations. Refer to [Appendix A: Pediatric Antiretroviral Drug Information](#) for additional information and recommended doses and formulations (also see Table 8 below). **In addition, many drugs that are recommended for use in newborns do not have dosing recommendations for premature infants. Additional information regarding dosing recommendations in this population can be found in [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#).**

**Children who are receiving effective and tolerable ARV regimens can continue using those regimens as they age, even if the combinations they are receiving are no longer *Preferred* regimens. Refer to the [Management of Children Receiving Antiretroviral Therapy](#) sections for decisions about transitioning children to other regimens as they grow.**

Preferred Initial Regimens Based on Age and Weight at Time of Treatment Initiation			
Age	Weight Restriction	Regimens	FDC Available (see <a href="#">Appendix A, Table 1</a> )
Newborns, Birth to Age <14 Days <sup>a,b</sup>	None	Two NRTIs <b>plus</b> NVP	No
	≥2 kg	Two NRTIs <b>plus</b> RAL <sup>c</sup>	No
Neonates ≥14 Days to Age <4 weeks	None	Two NRTIs <b>plus</b> LPV/r <sup>d</sup>	No
	≥2 kg	Two NRTIs <b>plus</b> RAL <sup>c</sup>	No
Infants and children Aged ≥4 Weeks	≥3 kg	Two NRTIs <b>plus</b> DTG <sup>d</sup> Two NRTIs <b>plus</b> DTG <sup>d</sup>	No Yes (≥25 kg)
<b>Children Aged ≥2 Years</b>	<b>≥14 kg</b>	Two NRTIs <b>plus</b> BIC <sup>e</sup>	Yes
Adolescents Aged ≥12 Years with SMRs of 4 or 5	Refer to the <a href="#">Adult and Adolescent Antiretroviral Guidelines</a>		Yes
Preferred Dual-NRTI Backbone Options for Use in Combination with Other Drugs			
Age	Dual-NRTI Backbone Options		FDC Available
Neonates Aged Birth to 1 Month	ABC <b>plus</b> (3TC or FTC) <sup>f</sup>		No <sup>g</sup>
	ZDV <b>plus</b> (3TC or FTC) <sup>h</sup>		No <sup>g</sup>
Infants and children Aged >1 Month to <2 Years	ABC <b>plus</b> (3TC or FTC) <sup>f</sup>		Yes
	ABC <b>plus</b> (3TC or FTC) <sup>f</sup>		Yes

<b>Children and Adolescents Aged <math>\geq 2</math> Years with SMRs of 1–3</b>	FTC/TAF <sup>i</sup> in children and adolescents weighing $\geq 14$ kg and receiving a regimen that contains an INSTI or an NNRTI FTC/TAF <sup>i</sup> in children and adolescents weighing $\geq 35$ kg and receiving a regimen that contains a boosted PI	Yes	
<b>Adolescents Aged <math>\geq 12</math> Years with SMRs of 4 or 5</b>	Refer to the <a href="#">Adult and Adolescent Antiretroviral Guidelines</a>	Yes	
<b>Alternative Regimens Based on Age and Weight at Time of Treatment Initiation</b>			
<b>Age</b>	<b>Weight Restriction</b>	<b>Regimens</b>	<b>FDC Available</b>
<b>Neonates, infants, and children Aged <math>\geq 14</math> Days to <math>&lt; 3</math> Years</b>	None	Two NRTIs plus NVP <sup>i</sup>	No
<b>Infants and children Aged <math>\geq 4</math> Weeks to <math>&lt; 3</math> Months</b>	None	Two NRTIs plus LPV/r <sup>b</sup>	No
	$\geq 2$ kg	Two NRTIs plus RAL <sup>c</sup>	No
<b>Infants and children Aged <math>\geq 3</math> Months to <math>&lt; 3</math> Years</b>	None	Two NRTIs plus ATV/r	No
	None	Two NRTIs plus LPV/r <sup>b</sup>	No
	None	Two NRTIs plus RAL <sup>c</sup>	No
<b>Children Aged <math>\geq 3</math> Years</b>	None	Two NRTIs plus ATV/r	No
	None	Two NRTIs plus DRV/r <sup>k</sup>	No
	None	Two NRTIs plus EFV <sup>l</sup>	No <sup>g</sup>
	None	Two NRTIs plus LPV/r <sup>b</sup>	No
	$\geq 25$ kg	Two NRTIs plus EVG/c <sup>m</sup>	Yes
	$\geq 35$ kg	Two NRTIs plus DOR <sup>n</sup>	Yes
<b>Adolescents Aged <math>\geq 12</math> Years with SMRs of 1–3</b>	None	Two NRTIs plus ATV/r	No
	None	Two NRTIs plus DRV/r <sup>k</sup>	No
	None	Two NRTIs plus EFV <sup>l</sup>	Yes
	None	Two NRTIs plus LPV/r <sup>b</sup>	No
	None	Two NRTIs plus RAL <sup>c</sup>	No
	$\geq 25$ kg	Two NRTIs plus EVG/c <sup>m</sup>	Yes
	$\geq 35$ kg	Two NRTIs plus ATV/c <sup>o</sup>	No
		Two NRTIs plus DOR <sup>n</sup>	Yes
		Two NRTIs plus RPV <sup>p</sup>	Yes
$\geq 40$ kg	Two NRTIs plus DRV/c <sup>q</sup>	Yes	
<b>Adolescents Aged <math>\geq 12</math> Years with SMRs of 4 or 5</b>	Refer to the <a href="#">Adult and Adolescent Antiretroviral Guidelines</a>	Yes	
<b>Alternative Dual-NRTI Backbone Options for Use in Combination with Other Drugs</b>			
<b>Age</b>	<b>Dual-NRTI Backbone Options</b>	<b>FDC Available</b>	
<b>Infants and children Aged <math>\geq 1</math> Month to <math>&lt; 6</math> Years</b>	ZDV plus (3TC or FTC) <sup>h</sup>	No <sup>g</sup>	
	ZDV plus ABC <sup>j</sup>	No	
<b>Children Aged <math>\geq 2</math> Years to 12 Years</b>	TDF plus (3TC or FTC) <sup>r</sup>	Yes	



Children and Adolescents Aged ≥6 Years and SMRs of 1–3	ZDV plus (3TC or FTC) <sup>h</sup>	Yes
	ZDV plus ABC <sup>f</sup>	No

<sup>a</sup> If treatment is scheduled to begin before a patient is aged 14 days, NVP or RAL are *Preferred* agents because they are the only options with dosing information available for this age group. Although many pediatric experts favor initiating antiretroviral therapy as soon as possible after birth to limit the establishment of viral reservoirs, available clinical trial data do not suggest that initiating treatment within the first 14 days of life leads to better clinical outcomes than initiating treatment after 14 days of age. Clinicians should consult an expert in pediatric HIV infection before initiating treatment in infants aged <14 days. Additional considerations regarding the use of NVP or RAL in infants aged <14 days can be found in [Antiretroviral Management of Newborns with Perinatal HIV Exposure or HIV Infection](#). Switching from NVP to LPV/r should be considered when the infant is aged ≥14 days with a postmenstrual age of 42 weeks (the span of time between the first day of the mother's last menstrual period and birth, plus the time elapsed after birth); LPV/r has produced better clinical outcomes than NVP in studies of children aged <3 years. Data are limited on the clinical outcomes of using RAL in infants and children aged <2 years.

<sup>b</sup> In general, LPV/r **should not be administered** to neonates before a postmenstrual age of 42 weeks and a postnatal age of ≥14 days (see the [Lopinavir/Ritonavir](#) section in [Appendix A: Pediatric Antiretroviral Drug Information](#)). Some experts would choose not to start with LPV/r as a *Preferred* initial regimen in neonates aged ≥14 days to <4 weeks but would choose to start with NVP instead.

<sup>c</sup> RAL granules can be administered to infants and children weighing ≥2 kg from birth to age 2 years. Oral RAL granules can be used up to a dose of 100 mg in the 14 kg to <20 kg weight band. RAL pills or chewable tablets can be used in children aged ≥2 years. Chewable RAL tablets can be crushed and dispersed in liquid and administered to infants as young as 4 weeks of age who weigh at least 3 kg.

<sup>d</sup> DTG is recommended as a *Preferred* agent for infants, children, and adolescents aged ≥4 weeks and weighing ≥3 kg. DTG dispersible tablets can be administered in infants and children aged ≥4 weeks and weighing ≥3 kg. DTG film-coated tablets can be used in children weighing ≥14 kg. An FDC tablet that contains ABC/DTG/3TC (Triumeq) is available for children weighing ≥25 kg.

<sup>e</sup> BIC is available only as part of an FDC tablet that contains BIC/FTC/TAF; this FDC tablet is recommended as a *Preferred* regimen for children weighing ≥14 kg. Two strengths of BIC/FTC/TAF are available, with dosing according to a child's weight (see [Bictegravir](#)).

<sup>f</sup> ABC is not approved by the U.S. Food and Drug Administration (FDA) for use in full-term neonates and infants aged <3 months. Recent data from the IMPAACT P1106 trial and two observational cohorts provide reassuring data on the safety of ABC in infants when initiated at the age of <3 months (see [Abacavir](#)). Before ABC administration, a negative HLA-B 5701 allele test should be available. An FDC tablet that contains ABC/3TC (Epzicom and generic) is available for use in children weighing ≥25 kg.

<sup>g</sup> FDA-approved FDC tablets are not included in this table when they are not approved for use in the specific patient populations being discussed.

<sup>h</sup> An FDC tablet that contains 3TC/ZDV (Combivir and generic) is available for use in children weighing ≥30 kg. Some members of the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) prefer ABC over ZDV because ABC can be dosed once daily.

<sup>i</sup> FTC plus TAF is recommended as a *Preferred* NRTI combination for children and adolescents weighing ≥14 kg when used with an INSTI or NNRTI; an FDC tablet that contains FTC/TAF (Descovy) is available in two strengths, with dosage determined by a child's weight (see [Tenofovir Alafenamide](#)). FTC/TAF is approved by the FDA for children weighing ≥14 kg when used in the regimen BIC/FTC/TAF, which is also available in two strengths, with dosage determined by a child's weight. EVG/c/FTC/TAF is approved for use in children weighing ≥25 kg. FTC/TAF is a *Preferred* NRTI combination for children and adolescents weighing ≥35 kg when used with a boosted PI; FTC/TAF is not approved or recommended for use with a boosted PI in children weighing <35 kg.

<sup>j</sup> NVP should not be used in post-pubertal girls with T lymphocyte cell counts >250/mm<sup>3</sup>, unless the benefit clearly outweighs the risk. NVP is approved by the FDA for the treatment of infants aged ≥15 days.

<sup>k</sup> DRV should only be used in children weighing ≥10 kg. Once-daily DRV should not be used in children aged <12 years or weighing <40 kg. Once-daily DRV should also not be used when any one of the following resistance-associated substitutions are present: V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V. DRV/r is recommended as an *Alternative* drug combination for children aged ≥6 years to <12 years and weighing >25 kg because there are other drugs that can be administered once daily and that are better tolerated. Note that DRV/r can be administered once daily in adolescents aged ≥12 years and weighing ≥40 kg who are not sexually mature (SMR 1–3).

<sup>l</sup> EFV is approved by the FDA for use in children aged  $\geq 3$  months and weighing  $\geq 3.5$  kg, but it **is not recommended** by the Panel for initial therapy in children aged  $\geq 3$  months to 3 years. FDC tablets that contain EFV/FTC/TDF (Atripla) and EFV 600 mg/3TC/TDF (Symfi) are available. See the [Efavirenz](#) section in [Appendix A: Pediatric Antiretroviral Drug Information](#) for information about use of the FDC EFV 400 mg/3TC/TDF (Symfi Lo).

<sup>m</sup> EVG is currently recommended only as a component of FDC tablets. Tablets that contain EVG/c/FTC/TAF (Genvoya) are recommended as an *Alternative* regimen for children and adolescents weighing  $\geq 25$  kg due to multiple drug–drug interactions from COBI and a lower barrier to the development of resistance to EVG.

<sup>n</sup> DOR is not FDA approved for pediatric use. Based on data from studies that evaluated the efficacy and tolerability of DOR in adults, as well as early findings from pediatric PK studies, the Panel recommends DOR as an *Alternative ARV* for children and adolescents weighing  $\geq 35$  kg. An FDC tablet containing DOR/3TC/TDF is available.

<sup>o</sup> ATV/c is available as an FDC tablet containing ATV/c (Evotaz) that has been approved by the FDA for use in children and adolescents weighing  $\geq 35$  kg.

<sup>p</sup> RPV should be administered to adolescents aged  $\geq 12$  years and weighing  $\geq 35$  kg who have initial viral loads  $\leq 100,000$  copies/mL. FDC tablets that contain FTC/RPV/TAF (Odefsey) and FTC/RPV/TDF (Complera) are available.

<sup>q</sup> DRV/c is available as part of an FDC tablet containing DRV/c/FTC/TAF (Symtuza) that has been approved by the FDA for use in children and adolescents weighing  $\geq 40$  kg.

<sup>r</sup> An FDC tablet that contains FTC/TDF (Truvada) is available.

**Key:** 3TC = lamivudine; ABC = abacavir; ATV/c = atazanavir/cobicistat; ATV/r = atazanavir/ritonavir; BIC = bictegravir; DOR = doravirine; DRV = darunavir; DRV/c = darunavir/cobicistat; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EFV = efavirenz; EVG = elvitegravir; EVG/c = elvitegravir/cobicistat; FDC = fixed-dose combination; FTC = emtricitabine; INSTI = integrase strand transfer inhibitor; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PK = pharmacokinetic; RAL = raltegravir; RPV = rilpivirine; SMR = sexual maturity rating; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine

**Table 8. Advantages and Disadvantages of Antiretroviral Components Recommended for Initial Therapy in Children**

See [Appendix A: Pediatric Antiretroviral Drug Information](#) and [Table 7. Antiretroviral Regimen Considerations for Initial Therapy Based on Specific Clinical Scenarios](#) in the [Adult and Adolescent Antiretroviral Guidelines](#) for more information.

ARV Class/ Agent(s)	Advantages	Disadvantages
All INSTIs	<p><b>INSTI Class Advantages</b></p> <ul style="list-style-type: none"> <li>• Few drug–drug interactions</li> <li>• Well tolerated</li> </ul>	<p><b>INSTI Class Disadvantages</b></p> <ul style="list-style-type: none"> <li>• Limited data on pediatric dosing or safety</li> <li>• Possible weight gain in adults, especially Black/African American women</li> </ul>
BIC	<p>Once-daily administration</p> <p>Can give with or without food</p> <p>Available in FDC tablets (see <a href="#">Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets</a>)</p>	<p>The FDC tablet <b>is not recommended</b> for patients with hepatic impairment or an estimated CrCl &lt;30 mL/min.</p> <p>The FDC tablet <b>should not be coadministered</b> with rifampin or dofetilide.</p>
DTG	<p>Once-daily administration</p> <p>Can give with food</p> <p>Available in FDC tablets (see <a href="#">Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets</a>)</p> <p>Single-agent DTG pills are available in several doses and are small in size.</p> <p>DTG is available as dispersible tablets for suspension.</p>	<p>Drug interactions with EFV, FPV/r, TPV/r, and rifampin, necessitating twice-daily dosing of DTG</p> <p>CNS side effects, particularly sleep disturbances.</p> <p>Early concerns about a possible increased risk of NTDs in infants born to women who were receiving DTG at the time of conception have decreased substantially. The Panel for Antiretroviral Guidelines for Adults and Adolescents and the Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission include DTG among the preferred ARV agents for use in people of childbearing potential and for use in people who are pregnant or are trying to conceive. Risks and benefits should be discussed to support informed decision making, see <a href="#">Dolutegravir, Appendix C: Antiretroviral Counseling Guide for Health Care Providers</a>.</p>
EVG	<p>Once-daily administration</p> <p>Available in FDC tablets (see <a href="#">Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets</a>)</p>	<p>Among INSTIs, EVG has the lowest barrier to the development of resistance.</p> <p>If EVG is coadministered with COBI, the potential exists for multiple drug interactions because COBI is metabolized by hepatic enzymes (e.g., CYP3A4).</p> <p>COBI inhibits tubular secretion of creatinine, and this may result in increased serum creatinine but normal glomerular clearance.</p>
RAL	<p>Can give with food</p> <p>Available in tablet, chewable tablet, and powder formulations</p>	<p>Potential for rare systemic allergic reaction or hepatitis</p> <p>Granule formulation requires a multistep preparation before administration; caregiver must be taught how to properly prepare this formulation.</p>

ARV Class/ Agent(s)	Advantages	Disadvantages
	<p>Chewable tablets can be crushed and mixed with various liquids for infants <math>\geq 4</math> weeks of age who weigh <math>\geq 3</math> kg.</p> <p>Once-daily administration (with RAL HD) can be used for treatment-naive or virologically suppressed children weighing <math>\geq 40</math> kg.</p>	
<b>All NNRTIs</b>	<p><b>NNRTI Class Advantages</b></p> <ul style="list-style-type: none"> <li>• Long half-life</li> <li>• Lower risk of dyslipidemia and fat maldistribution than PIs</li> <li>• PI-sparing</li> <li>• Lower pill burden than PIs for children taking the solid formulation; easier to use and adhere to than PI-based regimens</li> </ul>	<p><b>NNRTI Class Disadvantages</b></p> <ul style="list-style-type: none"> <li>• A single mutation can confer resistance, with cross-resistance between EFV and NVP.</li> <li>• Rare, but serious and potentially life-threatening, cases of skin rash (including SJS) and hepatic toxicity. All NNRTIs pose this risk, but the risk is greatest with NVP; these toxic effects have not been reported in neonates.</li> <li>• Potential for multiple drug interactions due to metabolism via hepatic enzymes (e.g., CYP3A4). Information about drug interactions is available in the <a href="#">Adult and Adolescent Antiretroviral Guidelines</a> and the <a href="#">HIV Drug Interaction Checker</a></li> </ul>
<b>DOR</b>	<p>Once-daily administration</p> <p>Available in FDC tablets (see <a href="#">Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets</a>)</p> <p>Can be taken with or without food</p> <p>Has continued antiviral activity in the setting of some NNRTI mutations</p>	<p>Neuropsychiatric AEs, but fewer than reported for EFV</p> <p>DOR is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers, see <a href="#">Doravirine</a>.</p> <p>Drug interactions between DOR and rifabutin induce the metabolism of DOR and require an additional dose of DOR 100 mg to be administered 12 hours after a fixed-dose combination of DOR/3TC/TDF or an increase of the DOR dose to 100 mg twice daily, see <a href="#">Doravirine</a>.</p>
<b>EFV</b>	<p>Once-daily administration</p> <p>Available in FDC tablets (see <a href="#">Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets</a>)</p> <p>Potent ARV activity</p> <p>Can give with food (but avoid high-fat meals)</p> <p>Capsules can be opened and added to food.</p>	<p>Neuropsychiatric AEs (bedtime dosing is recommended to reduce CNS effects)</p> <p>Rash (generally mild)</p> <p>No commercially available liquid formulation</p> <p>Limited data on dosing for children aged <math>&lt; 3</math> years</p> <p>No data on dosing for children aged <math>&lt; 3</math> months</p>
<b>NVP</b>	<p>Liquid formulation is available.</p> <p>Dosing information for young infants is available.</p> <p>Can give with food</p> <p>Extended-release formulation that allows once-daily dosing in older children is available.</p>	<p>Reduced virologic efficacy in young infants, regardless of exposure to NVP as part of a peripartum preventive regimen</p> <p>Higher incidence of rash/HSR than other NNRTIs</p> <p>Higher rates of serious hepatic toxicity than EFV</p> <p>Decreased virologic response compared with EFV</p>

ARV Class/ Agent(s)	Advantages	Disadvantages
		<p>Twice-daily dosing necessary in children with BSA &lt;0.58 m<sup>2</sup></p> <p>Low barrier to resistance</p>
<b>RPV</b>	<p>Once-daily dosing</p> <p>Available in FDC tablets (see <a href="#">Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets</a>)</p>	<p>Should not use in patients with viral loads &gt;100,000 copies/mL</p> <p>Must be taken with a ≥500 kcal meal at a consistent time each day; this may affect adherence.</p> <p>Low barrier to resistance</p>
<b>All PIs</b>	<p><b>PI Class Advantages</b></p> <ul style="list-style-type: none"> <li>• NNRTI-sparing</li> <li>• Clinical, virologic, and immunologic efficacy are well-documented.</li> <li>• Resistance to PIs requires multiple mutations.</li> <li>• When combined with a dual-NRTI backbone, a regimen that contains a PI targets HIV at two steps of viral replication by inhibiting the activity of viral reverse transcriptase and protease enzymes.</li> </ul>	<p><b>PI Class Disadvantages</b></p> <ul style="list-style-type: none"> <li>• Metabolic complications, including dyslipidemia, fat maldistribution, and insulin resistance</li> <li>• Potential for multiple drug interactions because of metabolism via hepatic enzymes (e.g., CYP3A4)</li> <li>• Higher pill burden than NRTI-based or NNRTI-based regimens for patients taking solid formulations</li> <li>• Poor palatability of liquid preparations, which may affect adherence</li> <li>• Most PIs require RTV boosting, resulting in drug interactions that are associated with RTV.</li> </ul>
<b>Boosted ATV</b>	<p>Once-daily dosing</p> <p>Powder formulation is available.</p> <p>ATV has less effect on TG and total cholesterol levels than other PIs (but RTV boosting may be associated with elevations in these parameters).</p>	<p>No liquid formulation</p> <p>Should be administered with food</p> <p>Indirect hyperbilirubinemia is common, but asymptomatic. Scleral icterus may be distressing to the patient, which may affect adherence.</p> <p>Must be used with caution in patients with preexisting conduction system defects (can prolong the PR interval of an ECG)</p> <p>RTV is associated with a large number of drug interactions.</p>
<b>Boosted DRV</b>	<p>Can be used once daily in children aged ≥12 years</p> <p>Liquid formulation is available.</p> <p>DRV requires a boosting agent.</p> <p>Available in FDC tablets (see <a href="#">Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets</a>)</p>	<p>Pediatric pill burden high with current tablet dose formulations</p> <p>Should be administered with food</p> <p>Must be boosted to achieve adequate plasma concentrations</p> <p>Contains sulfa moiety. The potential for cross-sensitivity between DRV and other drugs in sulfonamide class is unknown.</p> <p>RTV is associated with a large number of drug interactions.</p> <p>Can be used only once daily in the absence of certain PI-associated resistance mutations.</p>

ARV Class/ Agent(s)	Advantages	Disadvantages
<b>LPV/r</b>	<p>LPV is only available coformulated with RTV in liquid and tablet formulations.</p> <p>Tablets can be given without food, but they may be better tolerated when taken with a meal or snack.</p>	<p>Poor palatability of liquid formulation (bitter taste)</p> <p>Liquid formulation should be administered with food.</p> <p>RTV is associated with a large number of drug interactions.</p> <p>Should not be administered to neonates before a postmenstrual age of 42 weeks (the span of time between the first day of the mother's last menstrual period and birth, plus the time elapsed after birth) and a postnatal age <math>\geq 14</math> days</p> <p>Must be used with caution in patients with pre-existing conduction system defects (can prolong PR and QT interval of an ECG)</p>
<b>ABC plus (3TC or FTC)</b>	<p>Palatable liquid formulations</p> <p>Can give with food</p> <p>Available in FDC tablets (see <a href="#">Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets</a>)</p>	<p>Risk of ABC HSR; perform HLA-B*5701 screening before initiating ABC.</p>
<b>FTC/TAF for children aged <math>\geq 6</math> years</b>	<p>Once-daily dosing</p> <p>Small tablet size</p> <p>Lower risk of TFV-associated renal and bone toxicity with TAF than with TDF in adults</p> <p>Available in FDC tablets (see <a href="#">Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets</a>)</p>	<p>Limited data on the safety and efficacy of this combination in children</p> <p>Increased lipid levels</p>
<b>TDF plus (3TC or FTC) for adolescents with SMRs of 4 or 5</b>	<p>Once-daily dosing for TDF</p> <p>Resistance is slow to develop.</p> <p>Lower risk of mitochondrial toxicity than other NRTIs</p> <p>Can give with food</p> <p>Available as reduced-strength tablets and oral powder for use in younger children</p> <p>Available in FDC tablets (see <a href="#">Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets</a>)</p>	<p>Limited pediatric experience</p> <p>Potential bone and renal toxicity</p> <p>Appropriate dosing is complicated by numerous drug-drug interactions with other ARV agents, including ddl, LPV/r, ATV, and TPV.</p>
<b>ZDV plus (3TC or FTC)</b>	<p>Extensive pediatric experience</p> <p>Coformulations of ZDV and 3TC are available (Combivir and generic) for children weighing <math>\geq 30</math> kg.</p> <p>Palatable liquid formulations</p> <p>Can give with food</p> <p>FTC is available as a palatable liquid formulation that can be administered once daily.</p>	<p>Bone marrow suppression and lipoatrophy with ZDV</p> <p>ZDV requires twice-daily dosing.</p>

ARV Class/ Agent(s)	Advantages	Disadvantages
<b>ZDV plus ABC</b>	Palatable liquid formulations Can give with food	Risk of ABC HSR; perform HLA-B*5701 screening before initiating ABC.  Bone marrow suppression and lipoatrophy with ZDV ZDV requires twice-daily dosing.

**Key:** 3TC = lamivudine; ABC = abacavir; AE = adverse event; ARV = antiretroviral; ATV = atazanavir; BIC = bictegravir; BSA = body surface area; CNS = central nervous system; COBI = cobicistat; CrCl = creatinine clearance; CYP = cytochrome P450; ddI = didanosine; DOR = doravirine; DRV = darunavir; DTG = dolutegravir; ECG = electrocardiogram; EFV = efavirenz; EVG = elvitegravir; FDC = fixed-dose combination; FPV/r = fosamprenavir/ritonavir; FTC = emtricitabine; HD = high dose; HSR = hypersensitivity reaction; INSTI = integrase strand transfer inhibitor; LPV = lopinavir; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NTD = neural tube defect; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; RPV = rilpivirine; RTV = ritonavir; SJS = Stevens-Johnson Syndrome; SMR = sexual maturity rating; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TFV = tenofovir; TG = triglyceride; TPV = tipranavir; TPV/r = tipranavir/ritonavir; ZDV = zidovudine

## References

1. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. *N Engl J Med*. 2012;366(25):2380-2389. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22716976>.
2. Barlow-Mosha L, Angelidou K, Lindsey J, et al. Nevirapine- versus lopinavir/ritonavir-based antiretroviral therapy in HIV-infected infants and young children: long-term follow-up of the IMPAACT P1060 randomized trial. *Clin Infect Dis*. 2016;63(8):1113-1121. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27439527>.
3. Coovadia A, Abrams EJ, Stehla R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. *JAMA*. 2010;304(10):1082-1090. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20823434>.
4. Murnane PM, Stehla R, Shiao S, et al. Switching to efavirenz versus remaining on ritonavir-boosted lopinavir in HIV-infected children exposed to nevirapine: long-term outcomes of a randomized trial. *Clin Infect Dis*. 2017;65(3):477-485. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28419200>.
5. Babiker A, Castro nee Green H, Compagnucci A, et al. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. *Lancet Infect Dis*. 2011;11(4):273-283. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21288774>.
6. Ruel TD, Kakuru A, Ikilezi G, et al. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. *J Acquir Immune Defic Syndr*. 2014;65(5):535-541. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24326597>.
7. Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. *Lancet Infect Dis*. 2013;13(11):927-935. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24074642>.
8. Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO. *J Int AIDS Soc*. 2014;17(4 Suppl 3):19490. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25393999>.
9. Viani RM, Alvero C, Fenton T, et al. Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: 48-week results from IMPAACT P1093. *Pediatr Infect Dis J*. 2015;34(11):1207-1213. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26244832>.
10. Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile.



- Antimicrob Agents Chemother.* 2016;60(12):7086-7097. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27645238>.
11. Hassounah SA, Alikhani A, Oliveira M, et al. Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1. *Antimicrob Agents Chemother.* 2017;61(12):e01695-01617. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28923862>.
  12. Neogi U, Singh K, Aralaguppe SG, et al. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. *AIDS.* 2018;32(4):469-476. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29239896>.
  13. Oliveira M, Ibanescu RI, Anstett K, et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. *Retrovirology.* 2018;15(1):56. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30119633>.
  14. Gaur AH, Cotton MF, Rodriguez CA, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. *Lancet Child Adolesc Health.* 2021;5(9):642-651. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34302760>.
  15. Gaur A, Rodriguez C, McGrath, EJ, et al. Bictegravir/FTC/TAF single-tablet-regimen in adolescents: week 24 results. Presented at: Conference on Retroviruses and Opportunistic Infections. March 4–7; 2018. Boston, MA. Available at: <https://www.croiconference.org/abstract/bictegravirftctaf-single-tablet-regimen-adolescents-week-24-results>.
  16. Cotton M, Liberty A, Rodriguez CA, et al. Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single-tablet regimen in HIV-1-infected children (6 to <12 years) Presented at: International AIDS Conference 2018. Amsterdam, Netherlands. Available at: [http://www.natap.org/2018/IAC/IAC\\_39.htm](http://www.natap.org/2018/IAC/IAC_39.htm).
  17. Zash R, L. Holmes, M. Diseko, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Presented at: 23rd International AIDS Conference 2021; 2020. Virtual conference, July 6–10, 2020. Available at: [https://www.natap.org/2020/IAC/IAC\\_112.htm](https://www.natap.org/2020/IAC/IAC_112.htm).
  18. Rodriguez C, Chokephaibulkit K, Liberty A, et al. Safety, PK, and efficacy of low dose B/F/TAF in children  $\geq 2$  years old living with HIV. Presented at: Conference of Retroviruses and Opportunistic Infections; 2020. Boston, MA. Available at: <https://www.croiconference.org/abstract/safety-pk-and-efficacy-of-low-dose-b-f-taf-in-children-%e2%89%a52-years-old-living-with-hiv>.
  19. Ruel T, Farhad M, Alvero C, et al. Twenty-four week safety, tolerability and efficacy of dolutegravir dispersible tablets in children 4 weeks to <6 years old with HIV: results from IMPAACT P1093. Presented at: International AIDS Conference (AIDS 2020); 2020. San Francisco, California.

20. Wiznia A, Alvero C, Fenton T, et al. IMPAACT 1093: dolutegravir in 6- to 12-year-old HIV-infected children: 48-week results. Presented at: Conference on Retroviruses and Opportunistic Infections; 2016. Boston, MA.
21. Turkova A, White E, Mujuru HA, et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. *N Engl J Med.* 2021;385(27):2531-2543. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34965338>.
22. Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. *N Engl J Med.* 2019;381(9):827-840. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31329379>.
23. Zash R, Holmes L, Makhema J, et al. Surveillance for neural tube defects following antiretroviral exposure from conception. Presented at: 22nd International AIDS Conference; 2018. Amsterdam, Netherlands. Available at: [http://www.natap.org/2018/IAC/IAC\\_52.htm](http://www.natap.org/2018/IAC/IAC_52.htm).
24. Zash R, L. B. Holmes, M. Diseko, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Presented at: 24th International AIDS Conference 2021; 2021. Virtual, July 18-21, 2021.
25. Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naïve patients: week 96 and week 144 results from the SINGLE randomized clinical trial. *J Acquir Immune Defic Syndr.* 2015;70(5):515-519. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26262777>.
26. Viani RM, Ruel T, Alvero C, et al. Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: results of the IMPAACT P1093 study. *J Pediatric Infect Dis Soc.* 2019;9(2):159-165. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30951600>.
27. Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. *J Acquir Immune Defic Syndr.* 2014;65(3):e118-120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24256630>.
28. Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. *J Acquir Immune Defic Syndr.* 2014;65(3):e121-124. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24346640>.
29. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. *Lancet.* 2015;385(9987):2606-2615. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25890673>.
30. Natukunda E, Gaur A, Kosalaraksa P, et al. Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. *Lancet Child Adolescent*

- Health*. 2017;1(1):27-34. Available at:  
<http://www.sciencedirect.com/science/article/pii/S2352464217300093?via%3Dihub>.
31. Gaur AH, Kizito H, Prasitsuebsai W, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naïve, HIV-infected adolescents: a single-arm, open-label trial. *Lancet HIV*. 2016;3(12):e561-e568. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/27765666>.
  32. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. *Lancet*. 2009;374(9692):796-806. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19647866>.
  33. DeJesus E, Rockstroh JK, Lennox JL, et al. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. *HIV Clin Trials*. 2012;13(4):228-232. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22849964>.
  34. Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: final 5-year results from STARTMRK. *J Acquir Immune Defic Syndr*. 2013;63(1):77-85. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23412015>.
  35. Lennox JL, Landovitz RJ, Ribaldo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1: a randomized, controlled equivalence trial. *Ann Intern Med*. 2014;161(7):461-471. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25285539>.
  36. Briz V, Leon-Leal JA, Palladino C, et al. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents. *Pediatr Infect Dis J*. 2012;31(3):273-277. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/22330165>.
  37. Nachman S, Zheng N, Acosta EP, et al. Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. *Clin Infect Dis*. 2014;58(3):413-422. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24145879>.
  38. Nachman S, Alvero C, Acosta EP, et al. Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age. *J Pediatric Infect Dis Soc*. 2015;4(4):e76-83. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26582887>.
  39. Nachman S, Alvero C, Teppler H, et al. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial. *Lancet HIV*. 2018;5(12):e715-e722. Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/30527329>.
  40. Clarke DF, Acosta EP, Cababasay M, et al. Raltegravir (RAL) in neonates: dosing, pharmacokinetics (PK), and safety in HIV-1-exposed neonates at risk of infection

- (IMPAACT P1110). *J Acquir Immune Defic Syndr*. 2020;84(1):70-77. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31913995>.
41. Orkin C, Elion R, Thompson M, et al. Changes in weight and BMI with first-line doravirine-based therapy. *AIDS*. 2021;35(1):91-99. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33048879>.
  42. Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. *Lancet HIV*. 2018;5(5):e211-e220. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29592840>.
  43. Orkin C, Squires KE, Molina JM, et al. Doravirine/lamivudine/tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial. *Clin Infect Dis*. 2019;68(4):535-544. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30184165>.
  44. Melvin A, Best B, Muresan P, et al. IMPAACT 2014 24-week PK and safety of doravirine/3TC/TDF in adolescents with HIV-1. Presented at: Conference on Retroviruses and Opportunistic Infections; 2021. Virtual conference. Available at: <https://www.croiconference.org/abstract/impaact-2014-24-week-pk-and-safety-of-doravirine-3tc-tdf-in-adolescents-with-hiv-1>.
  45. Bwakura Dangarembizi M, Samson P, Capparelli EV, et al. Establishing dosing recommendations for efavirenz in HIV/TB-coinfected children younger than 3 years. *J Acquir Immune Defic Syndr*. 2019;81(4):473-480. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31241542>.
  46. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS clinical trials group 382 team. *N Engl J Med*. 1999;341(25):1874-1881. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10601506>.
  47. Teglas JP, Quartier P, Treluyer JM, Burgard M, Gregoire V, Blanche S. Tolerance of efavirenz in children. *AIDS*. 2001;15(2):241-243. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11216933>.
  48. Nunez M, Soriano V, Martin-Carbonero L, et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. *HIV Clin Trials*. 2002;3(3):186-194. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12032877>.
  49. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. *J Acquir Immune Defic Syndr*. 2004;36(5):1011-1019. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15247553>.
  50. Torti C, Maggiolo F, Patroni A, et al. Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-

- positive patients: results from the Italian MASTER cohort. *J Antimicrob Chemother.* 2005;56(1):190-195. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15917286>.
51. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. *N Engl J Med.* 2008;358(20):2095-2106. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18480202>.
  52. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. *J Infect Dis.* 2010;201(6):803-813. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20151839>.
  53. Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. *J Acquir Immune Defic Syndr.* 2012;60(1):33-42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22343174>.
  54. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. *Lancet.* 2012;379(9835):2439-2448. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22748591>.
  55. Spector SA, Hsia K, Yong FH, et al. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children. *J Infect Dis.* 2000;182(6):1769-1773. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11069252>.
  56. Starr SE, Fletcher CV, Spector SA, et al. Efavirenz liquid formulation in human immunodeficiency virus-infected children. *Pediatr Infect Dis J.* 2002;21(7):659-663. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12237599>.
  57. Fraaij PL, Neubert J, Bergshoeff AS, et al. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. *Antivir Ther.* 2004;9(2):297-299. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15134193>.
  58. Funk MB, Notheis G, Schuster T, et al. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. *Eur J Med Res.* 2005;10(12):503-508. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16356864>.
  59. McKinney RE, Jr., Rodman J, Hu C, et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS clinical trials group protocol P1021. *Pediatrics.* 2007;120(2):e416-423. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17646352>.
  60. Gutierrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. *Clin Infect Dis.* 2005;41(11):1648-1653. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16267739>.
  61. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected

- patients. *AIDS*. 2001;15(1):71-75. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11192870>.
62. Treisman GJ, Kaplin AI. Neurologic and psychiatric complications of antiretroviral agents. *AIDS*. 2002;16(9):1201-1215. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12045485>.
  63. Kaul S, Ji P, Lu M, Nguyen KL, Shangguan T, Grasela D. Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food. *Am J Health Syst Pharm*. 2010;67(3):217-222. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20101064>.
  64. Bardsley-Elliot A, Perry CM. Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. *Paediatr Drugs*. 2000;2(5):373-407. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11022799>.
  65. Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. *N Engl J Med*. 1997;336(19):1343-1349. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9134874>.
  66. Luzuriaga K, McManus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. *N Engl J Med*. 2004;350(24):2471-2480. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15190139>.
  67. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1-infected children. *AIDS*. 2003;17(11):1639-1647. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12853746>.
  68. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. *N Engl J Med*. 2010;363(16):1510-1520. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20942667>.
  69. Maswabi K, Ajibola G, Bennett K, et al. Safety and efficacy of starting antiretroviral therapy in the first week of life. *Clin Infect Dis*. 2021;72(3):388-393. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31927562>.
  70. Dhummakupt A, Persaud D. Capitalizing on postexposure antiretroviral prophylaxis to restrict seeding of the human immunodeficiency virus reservoir. *Clin Infect Dis*. 2021;73(3):439-440. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32503043>.
  71. Massanella M, Puthanakit T, Leyre L, et al. Continuous prophylactic antiretrovirals/antiretroviral therapy since birth reduces seeding and persistence of the viral reservoir in children vertically infected with human immunodeficiency virus. *Clin Infect Dis*. 2021;73(3):427-438. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32504081>.
  72. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. *Lancet*. 2004;363(9417):1253-1263. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15094269>.
  73. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naïve HIV-1

- patients: the ARTEN trial. *Antivir Ther*. 2011;16(3):339-348. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21555816>.
74. Kanya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2007;46(2):187-193. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17693883>.
  75. Lowenthal ED, Ellenberg JH, Machine E, et al. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children. *JAMA*. 2013;309(17):1803-1809. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23632724>.
  76. Buck WC, Kabue MM, Kazembe PN, Kline MW. Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. *J Int AIDS Soc*. 2010;13:31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20691049>.
  77. Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? *Lancet Infect Dis*. 2007;7(11):733-738. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17961859>.
  78. Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naive individuals. *Cochrane Database Syst Rev*. 2016;12:CD004246. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27943261>.
  79. Kekitiinwa A, Szubert AJ, Spyer M, et al. Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children. *Pediatr Infect Dis J*. 2017;36(6):588-594. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28505015>.
  80. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. *Lancet*. 2011;378(9787):229-237. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21763935>.
  81. Cohen CJ, Molina JM, Cassetti I, et al. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two phase III randomized trials. *AIDS*. 2013;27(6):939-950. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23211772>.
  82. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. *Lancet*. 2011;378(9787):238-246. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21763936>.
  83. Lombaard J, Bunupuradah T, Flynn PM, et al. Rilpivirine as a treatment for HIV-infected antiretroviral-naive adolescents: week 48 safety, efficacy, virology and pharmacokinetics. *Pediatr Infect Dis J*. 2016;35(11):1215-1221. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27294305>.

84. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results. *Clin Infect Dis*. 2007;44(11):1484-1492. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17479947>.
85. Cotton MF, Liberty A, Torres-Escobar I, et al. Safety and efficacy of atazanavir powder and ritonavir in HIV-1-infected infants and children from 3 months to <11 years of age: the PRINCE-2 study. *Pediatr Infect Dis J*. 2018;37(6):e149-e156. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29206747>.
86. Sevinsky H, Zaru L, Wang R, et al. Pharmacokinetics and pharmacodynamics of atazanavir in HIV-1-infected children treated with atazanavir powder and ritonavir: combined analysis of the PRINCE-1 and -2 studies. *Pediatr Infect Dis J*. 2018;37(6):e157-e165. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29206748>.
87. Malan DR, Krantz E, David N, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. *J Acquir Immune Defic Syndr*. 2008;47(2):161-167. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17971713>.
88. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. *J Acquir Immune Defic Syndr*. 2010;53(3):323-332. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20032785>.
89. Kiser JJ, Fletcher CV, Flynn PM, et al. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. *Antimicrob Agents Chemother*. 2008;52(2):631-637. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18025112>.
90. Kiser JJ, Rutstein RM, Samson P, et al. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. *AIDS*. 2011;25(12):1489-1496. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21610486>.
91. Rutstein RM, Samson P, Fenton T, et al. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the pediatric AIDS clinical trials group protocol 1020A. *Pediatr Infect Dis J*. 2015;34:162-167. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25232777>.
92. Strehlau R, Donati AP, Arce PM, et al. PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naive and -experienced infants and children aged  $\geq 3$  months to <6 years. *J Int AIDS Soc*. 2015;18:19467. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26066346>.
93. Kakuda TN, Brochot A, van de Castele T, Opsomer M, Tomaka F. Establishing darunavir dosing recommendations in treatment-naive and treatment-experienced pediatric patients. Presented at: 14th Clinical Pharmacology Workshop on HIV; 2013. Amsterdam, Netherlands. Available at: [http://www.natap.org/2013/Pharm/Pharm\\_19.htm](http://www.natap.org/2013/Pharm/Pharm_19.htm).



94. Larson KB, Cressey TR, Yogev R, et al. Pharmacokinetics of once-daily darunavir/ritonavir with and without etravirine in human immunodeficiency virus-infected children, adolescents, and young adults. *J Pediatric Infect Dis Soc.* 2016;5(2):131-137. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27199469>.
95. Food and Drug Administration. Tybost supplemental approval. 2019. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/applletter/2019/203094Orig1s013ltr.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2019/203094Orig1s013ltr.pdf)
96. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. *AIDS.* 2008;22(12):1389-1397. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18614861>.
97. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. *AIDS.* 2009;23(13):1679-1688. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19487905>.
98. King J, Hazra R, et al. Pharmacokinetics of darunavir 800 mg with ritonavir 100 mg once daily in HIV+ adolescents and young adults. Presented at: Conference on Retroviruses and Opportunistic Infections; 2013. Atlanta, GA.
99. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. *Lancet.* 2014;383(9936):2222-2231. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24698485>.
100. Flynn P, Komar S, Blanche S, et al. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naive, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE). *Pediatr Infect Dis J.* 2014;33(9):940-945. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25361024>.
101. Blanche S, Bologna R, Cahn P, et al. Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents. *AIDS.* 2009;23(15):2005-2013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19724191>.
102. Violari A, Bologna R, Kumarasamy N, et al. Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial. *Pediatr Infect Dis J.* 2015;34(5):e132-137. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25719453>.
103. Violari A, Masenya M, Blanche S, et al. The DIANA study: continued access to darunavir/ritonavir (DRV/r) and long-term safety follow-up in HIV-1-infected pediatric patients aged 3 to < 18 years. *Drug Saf.* 2021;44(4):439-446. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33367975>.
104. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. *J Acquir Immune Defic Syndr.* 2009;50(5):474-481. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19225400>.

105. van der Flier M, Verweel G, van der Knaap LC, et al. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily. *Antivir Ther.* 2008;13(8):1087-1090. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19195335>.
106. la Porte C, van Heeswijk R, Mitchell CD, Zhang G, Parker J, Rongkavilit C. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children. *Antivir Ther.* 2009;14(4):603-606. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19578247>.
107. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. *Lancet.* 2006;368(9534):476-482. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16890834>.
108. Pulido F, Estrada V, Baril JG, et al. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks. *HIV Clin Trials.* 2009;10(2):76-87. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19487177>.
109. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. *J Acquir Immune Defic Syndr.* 2009;50(4):367-374. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19214123>.
110. Orkin C, DeJesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. *HIV Med.* 2013;14(1):49-59. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23088336>.
111. Paediatric European Network for Treatment of AIDS. Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children. *AIDS.* 2015;29(18):2447-2457. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26558544>.
112. Paediatric European Network for Treatment of AIDS. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. *Lancet.* 2002;359(9308):733-740. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11888583>.
113. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. *Pediatrics.* 2006;118(3):e711-718. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16923923>.
114. Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Vigano A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. *J Acquir Immune Defic Syndr.* 2005;40(4):448-450. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16280700>.
115. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children.

- Antimicrob Agents Chemother.* 2004;48(1):124-129. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14693529>.
116. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. *Pediatrics.* 2005;116(6):e846-854. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16291735>.
  117. Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. *Antivir Ther.* 2006;11(3):377-384. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16759055>.
  118. Ross L, Parkin N, Chappey C, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. *AIDS.* 2004;18(12):1691-1696. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15280780>.
  119. Bekker A, Decloedt EH, Slade G, Cotton MF, Rabie H, Cressey TR. Single dose abacavir pharmacokinetics and safety in neonates exposed to human immunodeficiency virus (HIV). *Clin Infect Dis.* 2021;72(11):2032-2034. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32697327>.
  120. Bekker A, Capparelli EV, Violari A, et al. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. *Lancet HIV.* 2022;9(1):e24-e31. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34883066>.
  121. Green H, Gibb DM, Walker AS, et al. Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. *AIDS.* 2007;21(8):947-955. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17457088>.
  122. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. *N Engl J Med.* 2009;361(23):2230-2240. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19952143>.
  123. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. *AIDS.* 2009;23(12):1547-1556. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19542866>.
  124. Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. *Cochrane Database Syst Rev.* 2010(10):CD008740. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20927777>.
  125. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naïve, HIV-1-infected adults: 48-week results from the ASSERT study. *J Acquir Immune Defic Syndr.* 2010;55(1):49-57. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20431394>.

126. Mulenga V, Musiime V, Kekitiinwa A, et al. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. *Lancet Infect Dis*. 2016;16(2):169-179. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26481928>.
127. Technau KG, Lazarus E, Kuhn L, et al. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. *Pediatr Infect Dis J*. 2013;32(8):851-855. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23860481>.
128. Technau KG, Schomaker M, Kuhn L, et al. Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis. *Pediatr Infect Dis J*. 2014;33(6):617-622. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24378944>.
129. Cressey TR, Bekker A, Cababasay M, et al. Abacavir safety and pharmacokinetics in normal and low birth weight infants with HIV. Abstract#843. Presented at: Conference on Retroviruses and Opportunistic Infections; 2020. Boston, MA. Available at: <https://www.croiconference.org/abstract/abacavir-safety-and-pharmacokinetics-in-normal-and-low-birth-weight-infants-with-hiv>.
130. Crichton S, Collins IJ, Turkova A, et al. Abacavir dosing, effectiveness, and safety in young infants living with HIV in Europe. Abstract #844. Presented at: Conference on Retroviruses and Opportunistic Infections; 2020. Boston, MA. Available at: <https://www.croiconference.org/abstract/abacavir-dosing-effectiveness-and-safety-in-young-infants-living-with-hiv-in-europe>.
131. De Waal R, Rabie H, Technau K, et al. Abacavir safety and efficacy in young infants in South African observational cohort. Abstract #845. Presented at: Conference on Retroviruses and Opportunistic Infections; 2020. Boston, MA.
132. Bergshoeff A, Burger D, Verweij C, et al. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). *Antivir Ther*. 2005;10(2):239-246. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15865218>.
133. LePrevost M, Green H, Flynn J, et al. Adherence and acceptability of once daily lamivudine and abacavir in human immunodeficiency virus type-1 infected children. *Pediatr Infect Dis J*. 2006;25(6):533-537. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16732152>.
134. Paediatric European Network for Treatment of AIDS. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. *Antivir Ther*. 2010;15(3):297-305. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20516550>.
135. Musiime V, Kendall L, Bakeera-Kitaka S, et al. Pharmacokinetics and acceptability of once-versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW trial. *Antivir Ther*. 2010;15(8):1115-1124. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21149918>.

136. Natukunda E, Rodriguez C, McGrath E, et al. B/F/Taf in virologically suppressed adolescents and children: two-year outcomes in 6 to <18 year olds and six-month outcomes in toddlers. Presented at: 13th International Workshop on HIV Pediatrics; 2021. Virtual meeting. Available at: [https://www.natap.org/2021/IAS/IAS\\_80.htm](https://www.natap.org/2021/IAS/IAS_80.htm).
137. Descovy [package insert] [package insert]. Food and Drug Administration. 2021. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/208215s020lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208215s020lbl.pdf).
138. Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. *AIDS*. 2019;33(9):1455–1465. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30932951>.
139. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. *Lancet Infect Dis*. 2016;16(1):43-52. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26538525>.
140. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. *JAMA*. 2004;292(2):191-201. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15249568>.
141. Vigano A, Bedogni G, Manfredini V, et al. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. *Clin Drug Investig*. 2011;31(6):407-415. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21528939>.
142. Giacomet V, Maruca K, Ambrosi A, Zuccotti GV, Mora S. A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate. *Int J Antimicrob Agents*. 2017;50(3):365-370. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28689877>.
143. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. *N Engl J Med*. 2006;354(3):251-260. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16421366>.
144. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naïve patients: 144-week analysis. *J Acquir Immune Defic Syndr*. 2008;47(1):74-78. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17971715>.
145. Papaleo A, Warszawski J, Salomon R, et al. Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir. *Pediatr Infect Dis J*. 2007;26(10):949-951. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17901802>.
146. Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. *Pediatr Infect Dis J*. 2009;28(3):204-209. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19209091>.

147. Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. *Pediatr Infect Dis J*. 2009;28(7):619-625. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19561425>.
148. Pontrelli G, Cotugno N, Amodio D, et al. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors. *BMC Infect Dis*. 2012;12:18. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22269183>.
149. Van Dyke RB, Wang L, Williams PL, Pediatric AIDS Clinical Trials Group 219C Team. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. *J Infect Dis*. 2008;198(11):1599-1608. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19000014>.
150. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. *AIDS*. 2006;20(16):2043-2050. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17053350>.
151. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. *JAMA*. 2002;288(2):207-215. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12095385>.